CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- 8-K Event Material agreement · Executive or director change
- 4 Open-market sale Chief Executive Officer sold 90,000 shares at an average $169.22 ($15,230,000)
- 4 Shares withheld for taxes President and COO gave up 3,325 shares (to pay taxes)
- 4 Shares withheld for taxes EVP,Finance & Strategy and CFO gave up 2,111 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, Gen. Counsel & Secretary gave up 1,339 shares (to pay taxes)
- 4 Option exercise Director acquired 2,456 shares (option exercise)
- S-8 Other Securities Offered to Employees in Benefit Plans
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- UPLOAD Other SEC-generated Letter
- CORRESP Other Correspondence Between Filers and SEC Staff
- 4 Other acquisition Chief Executive Officer acquired 223 shares (other)
- UPLOAD Other SEC-generated Letter
- 8-K Event Other events
- 8-K Event Executive or director change · Shareholder vote results
- 8-K/A Event Exhibits
- 4 Option exercise Chief Executive Officer acquired 14,657 shares (option exercise)
- 8-K Event Other events
- 8-K Event Other events
- DEF 14A Proxy Proxy Statement
Page 27 of 115 · 2,300 filings